It is noted that the feasibility study conducted by T. Davidy et al. aimed to provide the basis for a multicenter, large-scale, randomized clinical trial of combining intranasal insulin with dulaglutide for improving cognition in older adults with metabolic syndrome who are at high risk of developing dementia [46]. The gene discussed is INS; the disease is dementia.